Supplement for "Improved Disease Control With Three-Week Infliximab Dosing in Severe Hidradenitis Suppurativa: A Retrospective Review"

Published: 12 June 2025| Version 1 | DOI: 10.17632/pw9kr5dyvj.1
Contributor:
Zahidul Islam

Description

PDF of Supplementary Tables Table 1: Inclusion and Exclusion Criteria Table 2: Infliximab Dosages and Concomitant Medications Before and During High-Frequency (every 3 weeks) Infliximab Therapy in Patients with Hidradenitis Suppurativa

Files

Categories

Dermatology, Immunomodulator, Hidradenitis Suppurativa

Licence